It shot to 53c and added a whole lot of new shareholders and awareness over this period, the pull back is healthy and for every sell it allows more LT holders to accumulate while some take profits.
Most / the majority of biotechs on the ASX pre revenue are undervalued and have a risked discount that is much higher than the USA or other countries for example. This is the opportunity for those of us investors that are willing to invest early.
Yes this company is P1, but we have a potential path to approval that’s near term & about 5-6yrs shorter than a typical biotech. It also has a very different risk profile to that of a company chasing cancer treatments where there’s many out there.
I’d encourage a different thought pattern here and not treating or analysing it in such a way.
Many people undervalued NEU & TLX… until they didn’t.
It shot to 53c and added a whole lot of new shareholders and...
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $86.90M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 25000 | 1 |
View Market Depth
| Last trade - 16.12pm 08/05/2024 (20 minute delay) ? |
| PAA (ASX) Chart |
Day chart unavailable